On the right track
Moving a drug from the lab bench to the pharmacy’s shelves takes about 10 years. But for one controversial autism treatment, the process might be much quicker.
Moving a drug from the lab bench to the pharmacy’s shelves takes about 10 years. But for one controversial autism treatment, the process might be much quicker.
There’s good news for autism research tucked into President Obama’s 2011 budget proposal: $222 million of it, to be exact.
On Saturday, a top government official resigned from the Interagency Autism Coordination Committee, the body of scientists and advocates that’s responsible for guiding all autism research funded by the U.S. National Institutes of Health. Institute director Francis Collins responds.
National Institutes of Health director Francis Collins talks about the agency’s upcoming plans for “beefing up” autism research, including more than $100 million each year in grants for the field.
It’s that time of year again — fall foliage, plump pumpkins and, if you’re a neuroscientist, the mad, mobbed scenes at the Society for Neuroscience (SFN) annual meeting.
Research on mouse models published in the past year is paving the way to reversing the symptoms of some autism-related disorders, National Institute Health directors told a packed room of 80 reporters at the morning at the Society for Neuroscience conference.
Even as I type this, thousands of neuroscientists are descending on Washington D.C. for an annual event that is almost beyond description. An estimated 36,000 people are expected to attend Neuroscience 2008, this yearʼs meeting of the Society for Neuroscience, hobnob, listen to lectures, present posters and down drinks at the many social events.